A Uterine cancer survival rate refers to the percentage of people who were reported still living after being diagnosed with the cancer about 5 yrs ago.
Endometrial carcinoma or Uterine Cancer is the most common malignancy of the female population. Each year, there are about 40,300 new cases diagnosed with this type of cancer, although in many occasions (around 75%), the diagnosis is established when the tumor is confined to the body of the uterus, therefore, many tumors can be cured. The 7,000 annual deaths caused by the cancer mean that this tumor ranks as the seventh leading cause of cancer death in women. It is primarily a neoplasm of postmenopausal women, although there are 25% of cases occurring in women under 50 years and 5% in women under 40 years. It is a predominantly common in Eastern Europe and the U.S. but quite rare in Asia.
Phenotypic traits and risk factors common in patients with endometrial cancer are obesity, menstrual disorders, a low fertility rate, late menopause, lack of ovulation and bleeding after menopausal. The risk is doubled in women taking tamoxifen to treat or prevent breast cancer. The maximum age of onset of endometrial carcinoma is the sixth and seventh decades of life. The symptoms are: abnormal vaginal discharge (90%), abnormal bleeding (80%), usually postmenopausal and vaginal discharge (10%). The study of patients with endometrial cancer may require a history and physical and gynecological examination, followed by endometrial biopsy or dilation of the cervix with fractional curettage. It may require an invasive procedure or minor surgery to establish the extent and degree of myometrial invasion or determine the staging. You have to take samples of peritoneal fluid, to explore the abdomen and pelvis, and perform a pelvic lymphadenectomy. As of today, around 74% of the patients are in stage I, 13% in stage II, 9% stage III, and 3% stage IV.
Uterine Cancer Survival rates at five years are as follows: Stage I: 89%, stage II: 80%, stage III: 30%, and stage IV: 9%.
A superficial invasion of the uterus (Stage I) can be treated with chemotherapy, but if the invasion is a bit larger, your doctor may suggest a radical hysterectomy or preoperative radiotherapy followed by extrafascial hysterectomy. About 15% of women with endometrial cancer are in stage II and the treatment depends on the intensity of this invasion. When the process has spread outside the uterus, but remains within the pelvis (stage III), treatment usually consists of surgery plus radiation. Patients whose cancer is only confined in the ovary and fallopian tubes, outcome with this treatment is quite high (80% uterine cancer survival rate at five years). Other stage III patients with a tumor spread beyond the Annexes and those with serous endometrial carcinoma have a significantly worse prognosis (uterine cancer survival rate of 15% at five years).
Source by Mert Ozge